ANI Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US00182C1036

Introduction

This page provides a comprehensive analysis of the known insider trading history of Daniel Raynor. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Daniel Raynor has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ANIP / ANI Pharmaceuticals, Inc. Director 289,003
US:EQTE / EQM Technologies & Energy, Inc. 10% Owner 952,381
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Daniel Raynor. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANIP / ANI Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANIP / ANI Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIP / ANI Pharmaceuticals, Inc. Insider Trades
Insider Sales ANIP / ANI Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANIP / ANI Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2018-03-19 ANIP RAYNOR DANIEL 5,313 60.6200 5,313 60.6200 322,074 277 41.17 -103,338 -32.09
2018-03-15 ANIP RAYNOR DANIEL 1,902 61.5000 1,902 61.5000 116,973
2018-03-14 ANIP RAYNOR DANIEL 1,919 62.0200 1,919 62.0200 119,016
2018-03-13 ANIP RAYNOR DANIEL 14,000 61.8100 14,000 61.8100 865,340
2018-03-13 ANIP RAYNOR DANIEL 4,117 62.5900 4,117 62.5900 257,683
2018-03-12 ANIP RAYNOR DANIEL 7,928 62.8800 7,928 62.8800 498,513
2015-03-12 ANIP RAYNOR DANIEL 200,000 63.0000 200,000 63.0000 12,600,000
2014-03-12 ANIP RAYNOR DANIEL 21,111 33.8900 21,111 33.8900 715,452
2014-03-12 ANIP RAYNOR DANIEL 19,213 33.8500 19,213 33.8500 650,360
2014-03-12 ANIP RAYNOR DANIEL 1,898 34.3500 1,898 34.3500 65,196

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIP / ANI Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Daniel Raynor as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2018-03-19 2018-03-19 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -5,313 289,003 -1.81 60.62 -322,074 17,519,362
2018-03-19 2018-03-15 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -1,902 294,316 -0.64 61.50 -116,973 18,100,434
2018-03-14 2018-03-14 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -1,919 296,218 -0.64 62.02 -119,016 18,371,440
2018-03-14 2018-03-13 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -4,117 298,137 -1.36 62.59 -257,683 18,660,395
2018-03-14 2018-03-13 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -14,000 302,254 -4.43 61.81 -865,340 18,682,320
2018-03-14 2018-03-12 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -7,928 316,254 -2.45 62.88 -498,513 19,886,052
2017-04-04 2017-03-31 4 ANIP ANI PHARMACEUTICALS INC
Stock Options
A - Award 2,000 2,000
2017-04-04 2017-03-31 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 1,000 11,110 9.89
2016-04-11 2016-04-07 4 ANIP ANI PHARMACEUTICALS INC
Option to Purchase
A - Award 2,000 2,000
2016-04-11 2016-04-07 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 1,000 10,110 10.98
2015-04-20 2015-04-16 4 ANIP ANI PHARMACEUTICALS INC
Option to Purchase
A - Award 1,600 1,600
2015-04-20 2015-04-16 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 800 9,110 9.63
2015-03-16 2015-03-12 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -200,000 324,182 -38.15 63.00 -12,600,000 20,423,466
2014-04-04 2014-04-01 4 ANIP ANI PHARMACEUTICALS INC
Option to Purchase
A - Award 2,500 2,500
2014-03-18 2014-03-14 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -12,347 524,182 -2.30 33.85 -417,946 17,743,561
2014-03-18 2014-03-12 4/A ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -1,898 536,529 -0.35 34.35 -65,196 18,429,771
2014-03-18 2014-03-12 4/A ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -19,213 538,427 -3.45 33.85 -650,360 18,225,754
2014-03-14 2014-03-12 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
S - Sale -21,111 3,324,738 -0.63 33.89 -715,452 112,675,371
2013-11-14 2013-11-12 4 EQTE EQM Technologies & Energy, Inc.
Series B Convertible Preferred Stock
A - Award 952,381 952,381
2013-11-14 2013-11-12 4 EQTE EQM Technologies & Energy, Inc.
Series A Convertible Preferred Stock
D - Sale to Issuer -952,381 0 -100.00
2013-11-04 2013-11-01 4 ANIP ANI PHARMACEUTICALS INC
Common Stock
A - Award 8,310 8,310
2013-07-29 3/A ANIP ANI PHARMACEUTICALS INC
Common Stock
3,345,849
2013-07-16 2013-07-12 4 BPAX BIOSANTE PHARMACEUTICALS INC
Option to Purchase
A - Award 20,000 20,000
2013-07-16 3 BPAX BIOSANTE PHARMACEUTICALS INC
Common Stock
3,345,849
2012-08-27 3 EQTE EQM Technologies & Energy, Inc.
Common Stock
21,037,043
2012-08-27 3 EQTE EQM Technologies & Energy, Inc.
Common Stock
172,774
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)